MarginsXMarginsX
Home › Markets › Health Care › HRTX

Heron Therapeutics Inc. (HRTX)

HRTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.2843
-8.44% on the day
Market cap
$54.1M
Micro cap
Revenue · 2025
$154.9M
+7.4% on 2024
Net income · 2025
-$20.2M
-13.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/818033/000119312526073515/0001193125-26-073515-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerHRTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000818033
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$154.9M
Net income-$20.2M
Operating income-$2.5M
Net margin-13.0%
Operating margin-1.6%
Revenue growth+7.4%
Cash$28.6M
Total assets$255.9M
P/E (computed)Net income was not positive
P/S (computed)0.3×

Warning signs

Cash runway
10.1 months
$11.6M cash at September 30, 2026
Share count, 1 year
+3.8%
2025-10-30 to 2026-11-04 · +26.8% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Liquidity and Going Concern In accordance with Accounting Standards Update ("ASU") No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40) , we have evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of iss"
10-Q 2026-11-09
Cash and burn$11.6M cash; operating cash flow -$3.4M a quarter.Report 2026-09-30
Shares outstanding190,273,587 (2026-11-04); 183,362,522 a year earlier; 150,072,640 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-06-25
AuditorWithumSmith+Brown, PC, Orlando, Florida, United StatesPCAOB Form AP 2026-03-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$35.3M-$5.0M-$794K$11.6MNo debt tags$148.2M10-Q 2026-11-09
Q2 2026
2026-06-30
$37.7M-$5.5M-$2.2M$20.7MNo debt tags$151.2M10-Q 2026-08-10
Q1 2026
2026-03-31
$34.7M-$8.1M-$1.5M$26.1MNo debt tags$150.7M10-Q 2026-05-11
Q4 2025
2025-12-31
$40.6M-$3.0M-$9.2M$28.6MNo debt tags$154.9M10-K 2026-02-26
Q3 2025
2025-09-30
$38.2M-$17.5M$1.3M$43.1MNo debt tags$155.1M10-Q 2026-11-09
Q2 2025
2025-06-30
$37.2M-$2.4M-$10.9M$16.5M$149.8M$149.7M10-Q 2026-08-10
Q1 2025
2025-03-31
$38.9M$2.6M-$8.9M$19.3MNo debt tags$148.5M10-Q 2026-05-11
Q4 2024
2024-12-31
$40.8M$3.7M-$11.8M$25.8MNo debt tags$144.3M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-09-09
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-11-09

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+6.9%
1 month-20.5%
3 months-6.1%
Year to date-76.2%
1 year-72.1%
From 52-week high-79.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
XLOXilio Therapeutics Inc.$7.70-3.08%$54.4M
AZRAzora Therapeutics Inc.$3.81-6.85%$54.4M
INCRIntercure Ltd.$3.63-4.22%$54.5M
CINGCingulate Inc.$3.75-12.79%$54.5M
VRCAVerrica Pharmaceuticals Inc.$3.20-10.11%$55.0M
SPROSpero Therapeutics Inc.$0.9464-5.35%$55.1M
CLNNClene Inc.$3.66-6.63%$52.7M
TNXPTonix Pharmaceuticals Holding Corp.$2.88-4.32%$56.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier